NOYA CoCr Biodegradable Coating Sirolimus-Eluting Coronary Stent System

May 20, 2012 updated by: Medfavour (Beijing) Medical Co., Ltd

Clinical Trial Program of a Medical Instrument Product

A single blind, multi-center, randomized study is preformed to compare NOYA CoCr biodegradable coating sirolimus-eluting stents with Firebird2 drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd. to evaluate the safety and efficacy of NOYA CoCr biodegradable coating sirolimus-eluting stents in treating coronary artery lesions.

Study Overview

Status

Unknown

Intervention / Treatment

Detailed Description

A single blind, multi-center, randomized study is preformed to compare NOYA CoCr biodegradable coating sirolimus-eluting stents with Firebird2 drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd. to evaluate the safety and efficacy of NOYA CoCr biodegradable coating sirolimus-eluting stents in treating coronary artery lesions. Appropriate patients judged by inclusion and exclusion standards will be preformed stent implantation, and after that all patients will be clinically followed up at 30, 90, 180, 270,365 days,2 years,3 years,4 years and 5 years. Especially, standard quantity coronary angiography (QCA) will be conducted at 270 days (±30days) through which the main therapeutic indicator of late luminal loss (LLL) is obtained so as to evaluate the efficacy of tested stents. Major adverse cardiac events (MACEs) found in following-up period as key indicators to evaluate the safety of stents. The arrangement, conclusion and statistical analysis of trial data including clinography and angiography will be fulfilled by independent Data Management Center(DMC) and radiography core laboratory.

Study Type

Interventional

Enrollment (Actual)

300

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Beijing, China, 100037
        • Fuwai Hospital, National Center for Cardiovascular Diseases

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age 18-75 years, men or unpregnant women;
  2. Angina pectoris patients with non-symptom myocardial ischemia, or patients with obsolete myocardial infarction;
  3. Total of lesion artery ≤2;
  4. Lesion artery ≤30 mm in length, 2.25 to 4.0 mm in diameter (ocular estimate);
  5. Narrow level of lesion artery ≥70% in diameter (ocular estimate);
  6. Amount of same stents implanted in a lesion artery ≤2;
  7. Patients with indications of coronary artery bridging surgery(coronary artery bypass transplant technique);
  8. Patients knowing about the objective of trial, willing to sign a statement of informed consent and join in this trial, and willing to accept follow-up.

Exclusion Criteria:

  1. Patients with acute myocardial infarction in 7 days;
  2. Chronic total occlusion lesions(TIMI 0 grade blood flow prior to implantation), left trunk vessel lesion, three-branch lesions needing treated, fork and bridge vessel lesions of branch vessels whose diameter ≥2.25mm;
  3. Severe calcific lesions and twisted lesions which cannot be pre-expanded, and lesions unsuitable for delivering and expanding stents;
  4. In-stent restenosis lesions;
  5. Patients with stent implantation in his/her coronary artery within recent one year;
  6. Severs heart failure(over NYHA III grade ), or left ventricular ejection fraction(LVEF)< 40%( supersonic inspection or left ventricular radiography );
  7. Kidney functional damage prior to implantation, serum creatinine level>2.0mg/dl;
  8. Patients with hemorrhage tendency, an active digestive ulcer history, a cerebral hemorrhage or subarachnoid hemorrhage history, or cerebral apoplexy within half a year, and these patients who contraindicate against platelet inhibitors and anticoagulant therefore can not bear anticoagulation treatment;
  9. Patients allergic to aspirin, clopidogrel or ticlopidine, heparin, contrast medium, rapamycin and metals;
  10. Patients whose life expectancy less than 12 months;
  11. Patients who are participating in other drugs or medical devices clinical trials;
  12. Patients who can not comply with the clinical trial protocol;
  13. Patients having a heart transplant.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: NOYA
implant NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stents Intervention: Device: stent

NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System is manufactured by Medfavour (Beijing) Medical Co., Ltd.

Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.

Other Names:
  • NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System
  • Firebird2 drug-eluting stents
Active Comparator: Firebird2
implant Firebird2 drug-eluting stents Intervention: Device: stent

NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System is manufactured by Medfavour (Beijing) Medical Co., Ltd.

Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.

Other Names:
  • NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System
  • Firebird2 drug-eluting stents

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
In-stent late loss at 9-month
Time Frame: 270 days (±30days)
Standard quantity coronary angiography (QCA) will be conducted at 270 days (±30days) through which the main therapeutic indicator of late luminal loss (LLL) is obtained so as to evaluate the efficacy of tested stents.
270 days (±30days)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
MACEs found in follow-up period
Time Frame: 5 years
Major adverse cardiac events (MACEs) found in following-up period as key indicators to evaluate the safety of stents.
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Runlin Gao, Professor, Fu Wai Hospital, National Center for Cardiovascular Diseases,China

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2009

Primary Completion (Actual)

December 1, 2010

Study Completion (Anticipated)

November 1, 2014

Study Registration Dates

First Submitted

October 21, 2010

First Submitted That Met QC Criteria

October 21, 2010

First Posted (Estimate)

October 22, 2010

Study Record Updates

Last Update Posted (Estimate)

May 22, 2012

Last Update Submitted That Met QC Criteria

May 20, 2012

Last Verified

May 1, 2012

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Diseases

Clinical Trials on stent

3
Subscribe